These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 28499383)

  • 1. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
    da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
    J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
    Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
    da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
    Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
    Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
    Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
    Alves LF; da Silva RF; Cagnon VHA
    Tissue Cell; 2018 Feb; 50():96-103. PubMed ID: 29429524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
    Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
    Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Montico F; Kido LA; Hetzl AC; Cagnon VH
    Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
    Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
    Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
    Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
    J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
    Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.
    da Silva RF; Dhar D; Raina K; Kumar D; Kant R; Cagnon VHA; Agarwal C; Agarwal R
    Sci Rep; 2018 Jun; 8(1):9540. PubMed ID: 29934570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
    Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
    J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
    Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
    Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
    Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
    Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
    Singh RP; Raina K; Sharma G; Agarwal R
    Clin Cancer Res; 2008 Dec; 14(23):7773-80. PubMed ID: 19047104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).
    Wadsworth TL; Worstell TR; Greenberg NM; Roselli CE
    Prostate; 2007 May; 67(6):661-73. PubMed ID: 17342743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
    Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
    Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.